Advert - Daiichi Sankyo – Case AUTH/3611/2/22

• Date posted
  16 June 2023
• Sanction
  Advertisement,
• Case number/s
  AUTH/3611/2/22 - Complainant v Daiichi Sankyo

For failing to make immediately apparent to health professionals in promotional material which referred to the therapeutic use of Nilemdo (bempedoic acid) or Nustendi (bempedoic acid and ezetimibe) in combination with a statin that there was a contraindication regarding concomitant use with simvastatin >40mg daily, Daiichi Sankyo was ruled in breach of the following Clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the
pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Misleading impression provided
Clause 6.2 - Misleading impression incapable of substantiation